Apple and Nokia have reached a deal after a testy legal dispute over the Finnish company’s patents.
The two sides announced the agreement in a joint statement yesterday, five months after they had sued each other over royalty payments.
The deal will see Apple make a sizeable one-off payment, as well as future fees, for the use of Nokia’s technology. Analysts estimated the deal was worth hundreds of millions of dollars to Nokia.
The company suffered immensely at the hands of the iPhone, and no longer makes handsets after selling its mobile business to Microsoft in 2013. While most of its revenue comes from telecoms infrastructure, it is seeking to bolster income from the valuable patents it still retains from its days as the world’s dominant mobile phone company.
After a long-running deal with Apple expired last year, Nokia sued it for violating 32 patents used in the iPhone. Apple sued back, calling Nokia a “patent troll” and saying it had refused to license the technology on a fair basis.
On Tuesday, the companies said they had settled all litigation and reached a new agreement. It will see Nokia’s healthcare gadgets return to Apple stores after they were removed last year, and the two companies said they might work together on healthcare initiatives.
Full Content: Apple
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas